Alumis

Kaken will hand Alumis $40 million in the near term for the rights to a late-stage tyrosine kinase 2 inhibitor as a dermatology treatment in Japan.

James Waldron Mar 25, 2025 6:55am

Mar 4, 2025 10:26am